Clinical Trial Update: Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating NY-ESO-1 overlapping peptides in epithelial ovarian, fallopian tube, or primary peritoneal cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• NY-ESO-1 overlapping peptides (NY-ESO-1 overlapping peptides)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Status: COMPLETED | Results posted: 2018-07-27